Piper Sandler Upgrades Immunogen Inc. (IMGN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Piper Sandler analyst Joseph Catanzaro upgraded Immunogen Inc. (NASDAQ: IMGN) from Neutral to Overweight with a price target of $16.00.
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $5.20 yesterday.
You May Also Be Interested In
- Citi Upgrades China Longyuan Power Group Corp (916:HK) (CLPXF) to Buy
- HSBC Upgrades Lenskart Solutions (LENSKART:IN) to Buy
- Kotak Upgrades Niva Bupa Health Insurance (NIVABUPA:IN) to Buy (1)
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
